Check Out Our Latest Analysis on Ascendis Pharma A/S Ascendis Pharma A/S Price Performance NASDAQ:ASND opened at $138.18 on Tuesday. The stock has a market cap of $8.39 billion, a P/E ratio of -19 ...

Ascendis Pharma A/S (NASDAQ:ASND – Free Report) – Analysts at Wedbush upped their FY2029 earnings per share (EPS) estimates for Ascendis Pharma A/S in a research note issued to investors on ...

BofA lowered the firm’s price target on Ascendis Pharma (ASND) to $192 from $203 and keeps a Buy rating on the shares. After Ascendis provided an early look at U.S. Yorvipath launch dynamics ...

Ascendis Pharma has piqued my interest due to its promising developments and strong pipeline. The company boasts several commercial stage products, indicating a robust foundation and growth ...

Ascendis Pharma announced the expiration of the regulatory waiting period for its collaboration agreement with Novo Nordisk, clearing the path for the development and commercialization of products ...

Ascendis Pharma (ASND) has released an update.Ascendis Pharma has entered a collaboration with Novo Nordisk to license its TransCon technology, aiming to develop treatments for metabolic and ...

Ascendis Pharma has emerged as a potential threat to BioMarin’s Voxzogo, reporting phase 3 growth disorder data that exceeded analyst expectations and position the biotech to file for approval ...

Ascendis, a biotech based in Denmark, took the wraps off its second quarter soon after market hours on Tuesday. The company posted revenue of slightly under 36 million euros ($40 million) for the ...

In trading on Wednesday, shares of Ascendis Pharma A/S (Symbol: ASND) crossed below their 200 day moving average of $133.67, changing hands as low as $114.50 per share. Ascendis Pharma A/S shares ...

The stock of Ascendis Pharma A/S jumped 4.5% Monday, after the biotech said the U.S. Food and Drug Administration has approved its Yorvipath as the first and only treatment for a rare endocrine ...

Ascendis Pharma should be well prepared for the U.S. launch of its hormone replacement therapy for hypoparathyroidism, which was approved on Friday by the FDA. After all, the company was initially ...